FAS
FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Cervical cancer and 5 more.
Overview
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signalling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.99, animal model 0.59, genetic association 0.18, somatic mutation 0.78). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Cervical Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Cervical cancer and 5 more.
- 1 · What it is
FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Cervical cancer and 5 more.
- 2 · What goes wrong in cancer
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor.
- 3 · How drugs use it
No product in this corpus aims at FAS yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:11920 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P25445 (protein name, function text, keywords and locations (REST API)); CIViC gene FAS (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000026103 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: melanoma 0.52, acute lymphoblastic leukaemia 0.50, diffuse large B-cell lymphoma 0.59, non-Hodgkin lymphoma 0.71, skin cancer 0.52, leukaemia 0.63 (GraphQL API, CC0)); IntOGen FAS (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signalling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). Location: Cell membrane; Membrane raft; Secreted (UniProt). Locus 10q23.31 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.71 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (MLYM)
- Leukaemia: Open Targets association 0.63 with leukaemia (MONDO_0005059)
- Cervical cancer: IntOGen driver in 1 cohort (CESC)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Diffuse large B-cell lymphoma: Open Targets association 0.59 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
- Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FAS" OR ABSTRACT:"FAS" OR TITLE:"Fas cell surface death receptor" OR ABSTRACT:"Fas cell surface death receptor" OR TITLE:"Tumor necrosis factor receptor superfamily member 6" OR ABSTRACT:"Tumor necrosis factor receptor superfamily member 6" OR TITLE:"CD95" OR ABSTRACT:"CD95" OR TITLE:"APO-1" OR ABSTRACT:"APO-1" OR TITLE:"FAS1" OR ABSTRACT:"FAS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAS, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTNFAIP3
Shares Marginal zone lymphoma, Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetPAX5
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetNFKBIE
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetTBL1XR1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetCNOT3
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetAFF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetBIRC3
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetTAL1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.